KIENDRA Film-coated tablet Ref.[115230] Active ingredients: Siponimod

Source: Health Products Regulatory Authority (ZA)  Revision Year: 2023  Publisher: Novartis SA (Pty) Ltd., Magwa Crescent West, Waterfall City, Johannesburg, 2090

Product name and form

KIENDRA 0.25 mg film-coated tablets.

KIENDRA 2 mg film-coated tablets.

Pharmaceutical Form

KIENDRA 0.25 mg: Pale red, round, biconvex, beveled-edged film-coated tablet with Novartis logo on one side and T on other side.

KIENDRA 2 mg: Pale yellow, round, biconvex, beveled-edged film-coated tablet with Novartis logo on one side and II on other side.

Qualitative and quantitative composition

KIENDRA 0.25 mg film-coated tablet contains 0,278 mg siponimod fumaric acid equivalent to 0,25 mg siponimod. Contains sugar: 62,2 mg lactose (as monohydrate) per tablet.

KIENDRA 2 mg film-coated tablet contains 2,224 mg siponimod fumaric acid equivalent to 2 mg siponimod. Contains sugar: 60,3 mg lactose (as monohydrate) per tablet.

For the full list of excipients see Section 6.1.

Active Ingredient

Siponimod is a sphingosine-1-phosphate (S1P) receptor modulator. By acting as a functional antagonist on S1P1 receptors on lymphocytes, siponimod prevents egress from lymph nodes. This reduces the recirculation of T cells into the central nervous system (CNS) to limit central inflammation. Siponimod is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease.

List of Excipients

Lactose monohydrate
Microcrystalline cellulose
Crospovidone
Glyceryl dibehenate
Silica
Colloidal anhydrous

Each 0.25 mg tablet contains 62.2 mg lactose monohydrate.

Each 2 mg tablet contains 60.3 mg lactose monohydrate.

Tablet coating:

Polyvinyl alcohol
Titanium dioxide
Iron oxide
Talc
Lecithin
Xanthan gum

Pack sizes and marketing

KIENDRA 0,25 mg film-coated tablets in blisters composed of PA/AL/PVC-AL blister packs. Pack sizes: 12 or 120 tablets per pack.

KIENDRA 2 mg film-coated tablets in blisters composed of PA/AL/PVC-AL blister packs. Pack sizes: 28 tablets per pack.

Marketing authorization holder

Novartis SA (Pty) Ltd., Magwa Crescent West, Waterfall City, Johannesburg, 2090

Marketing authorization dates and numbers

KIENDRA 0.25 mg: 54/34/0653
KIENDRA 2 mg: 54/34/0654

08 April 2021

Drugs

Drug Countries
KIENDRA South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.